Pivotal trial results for the IMbrave050 study, investigating atezolizumab plus bevacizumab as adjuvant therapy, were published on 2023-01-01. This study compared the combination therapy against active surveillance in patients with high-risk hepatocellular carcinoma after surgical resection or ablation.
Background
Atezolizumab (Tecentriq) is an immunotherapy drug. The IMbrave050 study focused on its use, in combination with bevacizumab, for hepatocellular carcinoma (HCC), a primary liver cancer. The trial specifically addressed patients at high risk of recurrence following surgical resection or ablation.
Trial design
The IMbrave050 study was a randomised, open-label trial. It investigated atezolizumab plus bevacizumab as adjuvant therapy compared to active surveillance. The study population included patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation.
What this means
The publication of the IMbrave050 trial results means that the detailed findings of this study, evaluating atezolizumab plus bevacizumab as adjuvant therapy for high-risk hepatocellular carcinoma, are now accessible to the medical and research communities. Clinicians and researchers can review the full data to understand the potential role of this combination therapy in preventing recurrence in this patient population.
Source
The information regarding the IMbrave050 trial results was published on 2023-01-01. The publication, titled "Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, ope", was sourced from PubMed, hosted at pubmed.ncbi.nlm.nih.gov.